Laurie Sehn

Laurie Sehn is Canada's foremost DLBCL clinician who has contributed extensively to real-world outcomes research in DLBCL and validated the predictive value of the International Prognostic Index (IPI). She has led Canadian multicenter studies characterizing patterns of relapse, salvage therapy outcomes, and implementation of novel regimens including polatuzumab vedotin plus bendamustine-rituximab in relapsed/refractory DLBCL. Her work also covers barriers to CAR-T access and outcomes in elderly DLBCL patients ineligible for intensive therapy.